Index -
P/E -
EPS (ttm) -1.15
Insider Own 16.62%
Shs Outstand 14.47M
Perf Week 6.60%
Market Cap 33.22M
Forward P/E -
EPS next Y -1.48
Insider Trans 0.00%
Shs Float 13.19M
Perf Month 28.44%
Income -14.58M
PEG -
EPS next Q -0.15
Inst Own 7.61%
Short Float 4.67%
Perf Quarter -25.00%
Sales 0.00M
P/S -
EPS this Y 46.09%
Inst Trans 129.36%
Short Ratio 7.75
Perf Half Y -45.45%
Book/sh 0.32
P/B 6.51
EPS next Y -138.71%
ROA -170.64%
Short Interest 0.62M
Perf Year -30.69%
Cash/sh 0.47
P/C 4.45
EPS next 5Y -
ROE -243.33%
52W Range 1.17 - 8.82
Perf YTD -45.17%
Dividend Est. -
P/FCF -
EPS past 5Y -17.77%
ROI -312.38%
52W High -76.19%
Beta -1.79
Dividend TTM -
Quick Ratio 2.53
Sales past 5Y 0.00%
Gross Margin -
52W Low 79.49%
ATR (14) 0.16
Dividend Ex-Date -
Current Ratio 2.53
EPS Y/Y TTM -3.29%
Oper. Margin 0.00%
RSI (14) 50.58
Volatility 6.13% 9.23%
Employees 4
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 12.00
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -35.24%
Payout -
Rel Volume 0.81
Prev Close 2.09
Sales Surprise -
EPS Surprise -51.02%
Sales Q/Q -
Earnings May 15 BMO
Avg Volume 79.44K
Price 2.10
SMA20 3.17%
SMA50 -4.99%
SMA200 -27.41%
Trades
Volume 4,790
Change 0.48%
May-02-24 07:00AM
Apr-25-24 10:12AM
Apr-23-24 10:57AM
Mar-21-24 03:01AM
Mar-19-24 09:32AM
10:01PM
Loading…
Mar-18-24 10:01PM
(Thomson Reuters StreetEvents)
09:52AM
07:01AM
Mar-04-24 07:01AM
Feb-27-24 07:01AM
Feb-23-24 09:30AM
Feb-16-24 09:30AM
Feb-02-24 09:30AM
Feb-01-24 09:33AM
Jan-29-24 07:00AM
10:55AM
Loading…
Jan-26-24 10:55AM
Jan-23-24 07:01AM
Jan-19-24 09:30AM
Jan-17-24 01:26PM
07:01AM
Jan-05-24 09:30AM
Jan-03-24 08:00AM
Dec-11-23 07:01AM
Dec-08-23 09:46AM
Dec-07-23 09:20AM
Dec-01-23 09:30AM
Nov-24-23 09:30AM
Nov-17-23 09:30AM
Nov-15-23 02:35PM
Nov-14-23 07:01AM
08:52AM
Loading…
Nov-09-23 08:52AM
Nov-02-23 07:01AM
Oct-25-23 07:01AM
Oct-20-23 10:43AM
Oct-19-23 07:01AM
Oct-02-23 07:01AM
Sep-12-23 07:01AM
Aug-22-23 07:01AM
Aug-14-23 07:01AM
Jul-24-23 07:01AM
Jul-11-23 07:00AM
Jul-07-23 09:30AM
Jun-30-23 09:35AM
Jun-20-23 07:01AM
Jun-15-23 07:01AM
May-16-23 08:45AM
May-12-23 07:01AM
May-05-23 05:01PM
Apr-22-23 09:42AM
Apr-21-23 09:30AM
Apr-19-23 07:01AM
Apr-13-23 09:30AM
Apr-11-23 07:01AM
Mar-23-23 04:00PM
Mar-18-23 02:03AM
Mar-16-23 07:01AM
Mar-06-23 08:00AM
Feb-14-23 08:01AM
Feb-07-23 08:49AM
Jan-24-23 07:00AM
Jan-19-23 09:00AM
Jan-16-23 08:01AM
Dec-29-22 06:02AM
Dec-28-22 10:39AM
Nov-14-22 07:01AM
Nov-13-22 08:31AM
Nov-04-22 09:30AM
Nov-01-22 08:01AM
Oct-26-22 08:01AM
Oct-17-22 08:00AM
Oct-10-22 09:30AM
Oct-07-22 09:30AM
Sep-26-22 09:30AM
Sep-23-22 10:15AM
Sep-16-22 09:30AM
Aug-15-22 07:01AM
Aug-04-22 08:01AM
Aug-02-22 09:00AM
Jul-25-22 08:30AM
May-11-22 07:01AM
Apr-29-22 08:01AM
Mar-24-22 03:23PM
Mar-17-22 07:01AM
Mar-16-22 08:01AM
Mar-07-22 08:01AM
Feb-07-22 08:01AM
Dec-06-21 08:01AM
Nov-12-21 06:01PM
Nov-08-21 08:01AM
Nov-01-21 08:01AM
Oct-27-21 08:01AM
Oct-04-21 09:00AM
Sep-30-21 08:00AM
Sep-29-21 08:00AM
Sep-27-21 08:00AM
Sep-25-21 08:02AM
Sep-13-21 08:03AM
Sep-02-21 08:00AM
Aug-31-21 08:00AM
Aug-17-21 07:00AM
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Sailer Carl Director Jan 19 '24 Option Exercise 3.55 19,737 70,066 112,552 Jan 22 06:15 AM DELUCCIA ROBERT J Director Jan 03 '24 Option Exercise 3.55 19,737 70,066 960,935 Jan 04 04:26 PM LUCI DAVID P President and CEO Jan 03 '24 Option Exercise 3.55 19,737 70,066 1,048,197 Jan 04 04:24 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite